Bhavana J. Dave, PhD, FACMG

Bhavana DaveBhavana J. Dave, PhD, FACMG
Human Genetics Laboratory
Munroe-Meyer Institute
985440 Nebraska Medical Center
Omaha, NE 68198-5440

Phone: (402) 559-9914
E-mail: bdave@unmc.edu

Professional Summary:

 

Bhavana Dave, Ph.D., FACMG, is Professor and Associate Director of the Human Genetics Laboratories at the University of Nebraska Medical Center, Munroe-Meyer Institute. Dr Dave is board certified in Clinical Cytogenetics by the American Board of Medical Genetics and she is a Fellow of American College of Medical Genetics. Dr Dave has been involved in patient care by providing clinical cytogenetic services utilizing cutting edge diagnostic tests including fluorescence in situ hybridization (FISH) and array based comparative genomic hybridization (aCGH). Dr Dave serves as a reviewer and is on the editorial board of Medical Genetics and Cancer Biology related journals.

Dr Dave’s research involves in-depth genetic characterization of lymphomas and leukemias and delineating the basic mechanisms of the genetic abnormalities that allows us to better comprehend the consequences of genetic changes and eventually leads to better disease management. Dr Dave is actively involved in translational research which expands our understanding of genetic diagnosis impacting the prognosis and management of a variety of diseases including cancer, developmental and prenatal disorders.

Education:

FACMG, Fellow of American College of Medical Genetics (Clinical Cytogenetics)
PhD, Maharaja Sayajirao Gujarat University, Baroda, Gujarat, India
BS, MS, Gujarat University, Ahmedabad, India

Courses Taught:

UNMC, PEDS 911 - Human Genetics and Cytogenetics Principles
UNMC, PEDS 912 - Human Cytogenetics Laboratory
Human Cytogenetics – Lectures and Case Reviews in Elective Rotations for Pathology, Pediatrics, and Internal Medicine Residents

Research Interests and Projects:

  • Chromosome 1p36 in angiogenesis and progression of Non Hodgkin Lymphoma
  • Role of TP73 in non Hodgkin Lymphoma progression
  • Lymphoma Defined Cytogenetically for Epidemiologic Study
  • Molecular Signatures to Improve Diagnosis and Outcome Prediction in NHL
  • Genetic Abnormalities in Follicular and Transformed Follicular Lymphoma
  • Genetic Pathways in the Evolution of Follicular Lymphoma
  • Epigenetic effects of Biotin on activation of endogenous retroviral sequences
  • Defining molecular subtypes of lymphoma for relevance to survival, etiology, and diagnosis
  • Case Control study of Pesticides and t(14;18) Lymphoma
  • Molecular Genetics of NHL: add(1)(p36) and add(14)(q32)
  • Genetics of Pediatric Hodgkin’s Disease
  • GENUS™ for automated karyotyping of multiple animal and plant species

Selected Publications: (within the last 5 years)

  • Chang CM, Wang SS, Dave BJ, Jain S, Vasef MA, Weisenburger DD, Cozen W, Davis S, Severson RL, Lynch CF, Rothman N, Cerhan JR, Hartge P, Morton LM. Risk factors for non-Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population-based  case control study. Int J Cancer Oct 2010 Epub ahead of print PMID 20949561.
  • Eudy JE, Pickering DL, Lutz R, Platt K, Olney AH, Dave BJ, Sanger WG. Familial 18q22.3→18q23 Deletion Syndrome. Am J Med Genet A. 2010;152A(4):1046-1048.
  • Nelson M, Perkins SL, Dave BJ, Coccia PF, Bridge JA, Lyden ER, Heerema NA, Lones MA, Cairo MS and Sanger WG. An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children’s Cancer Group study CCG-5961. British J Hematol 2010;148(4):600-610.
  • Dave BJ, Olney AH, Zaleski DH, Pickering DL, Becker TA, Chipman H, Sanger WG. Inherited 14q Duplication and 21q Deletion: A Rare Adjacent-2 Segregation in Multiple Family Members. American J Med Genet A 2009;149A(10):2248-2253.
  • Gu K, Fu K, Jain S, Liu Z, Iqbal J, Li M, Sanger WG, Weisenburger DD, Greiner TC, Aoun P, Dave BJ and Chan WC. t(14;18)-negative Follicular Lymphomas Are Associated with a High Frequency of BCL6 Rearrangement at the Alternative Breakpoint Region. Mod Pathol 2009;22(9):1251-1257.
  • Chew YC, West JT, Kratzer SJ, Ilvarsonn AM, Eissenberg JC, Dave BJ,Klinkebiel D, Christman JK, and Zempleni J. A diet-dependent epigenetic mechanism that represses transposable elements. J Nutr 2008;138:2316-2322.
  • D’Amore F, Chan E, Iqbal J, Geng H, Young K, Li X, Hess MM, Sanger WG, Wiuf C, Hagberg O, Fu K, Chan WC, and Dave BJ.Clonal Evolution in t(14;18)-positive follicular lymphoma, evidence for multiple common pathways and frequent parallel clonal evolution. Clin Cancer Res 2008;14(22):7180-7187.
  • Chiu B C-H, Dave BJ,Ward MH, Hou L, Fought AJ, Jain S, Evens AM, Zahm SH, Blair A, and Weisenburger DD. Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma. Cancer Causes and Control. 2008;19(8):859-867.
  • Chiu B C-H, Lan Q, Dave BJ, Blair A, Zahm SH, and Weisenburger DD. The utility of t(14;18) in understanding risk factors for non-Hodgkin lymphoma. J Natl Cancer Inst Monogr. 2008;39:69-73.
  • Bakshi SR, Dave BJ,Sanger W, Patel SJ, Trivedi PJ, and Brahmbhatt MM. Characterization of a small familial supernumerary marker chromosome in a patient with adult onset tongue cancer. Cytogenet and Genome Res. 2008;121(1):14-17.
  • Pickering DL, Eudy JD, Olney A, Dave BJ,Golden D, Stevens J, and Sanger WG. Array-CGH Analysis of 1176 Consecutive Clinical Genetics Investigations. Genet Med. 2008;10(4):262-266.
  • Nelson M, Horsman DE, Weisenburger DD, Gascoyne RD, Dave BJ, Loberiza FR, Ludkovski O, Savage KJ, Armitage JO, and Sanger WG. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Hematol. 2008;141(4):461-469.
  • Young KH, Weisenburger DD, Dave BJ,Smith L, Sanger WG, Campo E, Delabie J, Gascoyne RD, Rimza L, Müeller-Hermelink HK, Jaffe ES, Rosenwald A, Staudt LM, Chan WC and Greiner TC. Mutations in the DNA-Binding Codons of TP53 Predict for Poor Survival and Molecular Profiling Suggests TRAIL Receptor-2 for Targeted Therapy in Diffuse Large B-Cell Lymphoma. Blood. 2007;110(13):4396-4405.
  • Iqbal J, Greiner TC, Patel K, Dave BJ,Smith L, Ji J, Sanger WG, Pickering DL, Jain S, Wright G, Horsman D, Shen Y, Fu K, Weisenburger DD, Campo E, Gascoyne RD, Rosenwald A, Jaffe ES, Ott G, Delabie J, Rimsza L, Connors JM, Vose JM, McKeithan T, Staudt LM and Chan WC For the Leukemia/Lymphoma Molecular Profiling Project (LLMPP). Distinctive patterns of BCL6 molecular alterations in different subgroups of diffuse large B-cell lymphoma and their functional consequences. Leukemia. 2007; 21(11):2332-2343.
  • Mittal AK, Hegde GV, Aoun P, Bociek RG, Dave BJ, Joshi AD, Sanger WG, Weisenburger DD, and Joshi SS. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities. Int J Mol Medicine. 2007;20(4):461-469.
    Dave BJ and Sanger WG. Role of Cytogenetics and Molecular Cytogenetics in the diagnosis of genetic imbalances. Semin Pediatr Neurol. 2007;14(1);2-6.
  • Chiu B C-H, Dave BJ,Blair A, Chmiel JS, Fought AJ, Gapstur SM, Zahm SH, and Weisenburger DD. Cigarette smoking, familial cancer and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma. Am J Epidemiol. 2007;165:652-659.
  • Chiu B C-H, Dave BJ,Blair A, Gapstur SM, Zahm SH, and Weisenburger DD. Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma. Blood. 2006;108(4):1363-1369.
  • Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. Molecular Diagnosis of Burkitt’s Lymphoma. New Engl. J of Med. 2006;354(23):2431-2442.
  • Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, Lynch J, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Campo E, Ott G, H. Müller-Hermelink K, Delabie J, Jaffe ES, Grogan TM, Connors JM, Vose JM, Armitage JO, Staudt LM, and Chan WC, for the Leukemia/Lymphoma Molecular Profiling Project. BCL2 expression is a prognostic marker for activated B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(6):1-8.
  • Giampietro PF, Babu D, Zabel C, Silberman T, Zador I, DeBauche D, Britt Ravnan J, and Dave BJ. Novel Clinical Features in a Child with Partial Deletion of Chromosome 11 [del(11)(q24.2)]: Further Evidence for Phenotypic Heterogeneity. Am J Med Genet. A. 2006;140A(4):385-387.

Professional Affiliations:

  • American Association for Cancer Research
  • American Society of Human Genetics
  • American College of Medical Genetics
  • Association of Genetic Technologists
  • Indian Association for Cancer Research
  • Indian Society of Cell Biology